Literature DB >> 28983651

[Cytoreductive, radical prostatectomy in metastatic prostate cancer].

M Chaloupka1, A Herlemann2, A Spek2, C Gratzke2, C Stief2.   

Abstract

The resection of the primary tumor in patients with metastatic prostate cancer is controversially debated. Retrospective clinical studies indicate survival benefits and prevention of secondary, locoregional complications; however, results of ongoing multicenter prospective studies are still lacking. This review highlights the rationale behind the cytoreductive prostatectomy and summarizes current clinical study results.

Entities:  

Keywords:  Bone metastasis; Brachytherapy; Cytoreductive surgery; Lymphnode metastasis; Malignancy; Secondary complications, locoregional

Mesh：

Year:  2017        PMID： 28983651     DOI： 10.1007/s00120-017-0505-2

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  23 in total

1.  A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation.

Authors:  Prasanna Sooriakumaran; Jeffrey Karnes; Christian Stief; Bethan Copsey; Francesco Montorsi; Peter Hammerer; Burkhard Beyer; Marco Moschini; Christian Gratzke; Thomas Steuber; Nazareno Suardi; Alberto Briganti; Lukas Manka; Tommy Nyberg; Susan J Dutton; Peter Wiklund; Markus Graefen
Journal:  Eur Urol       Date:  2015-05-30       Impact factor: 20.096

2.  Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry.

Authors:  Christian Gratzke; Jutta Engel; Christian G Stief
Journal:  Eur Urol       Date:  2014-05-10       Impact factor: 20.096

3.  Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome.

Authors:  Anna Patrikidou; Laurent Brureau; Julien Casenave; Laurence Albiges; Mario Di Palma; Jean-Jacques Patard; Hervé Baumert; Pierre Blanchard; Alberto Bossi; Kyriaki Kitikidou; Christophe Massard; Karim Fizazi; Pascal Blanchet; Yohann Loriot
Journal:  Urol Oncol       Date:  2015-03-05       Impact factor: 3.498

4.  Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.

Authors:  Charles J Ryan; Eric P Elkin; Eric J Small; Janeen Duchane; Peter Carroll
Journal:  Urol Oncol       Date:  2006 Sep-Oct       Impact factor: 3.498

5.  Local Therapy Improves Survival in Metastatic Prostate Cancer.

Authors:  Sami-Ramzi Leyh-Bannurah; Stéphanie Gazdovich; Lars Budäus; Emanuele Zaffuto; Alberto Briganti; Firas Abdollah; Francesco Montorsi; Jonas Schiffmann; Mani Menon; Shahrokh F Shariat; Margit Fisch; Felix Chun; Thomas Steuber; Hartwig Huland; Markus Graefen; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2017-04-03       Impact factor: 20.096

6.  Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.

Authors:  Raj Satkunasivam; Andre E Kim; Mihir Desai; Mike M Nguyen; David I Quinn; Leslie Ballas; Juan Pablo Lewinger; Mariana C Stern; Ann S Hamilton; Monish Aron; Inderbir S Gill
Journal:  J Urol       Date:  2015-02-21       Impact factor: 7.450

Review 7.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

Review 8.  Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons.

Authors:  M Quinn; P Babb
Journal:  BJU Int       Date:  2002-07       Impact factor: 5.588

9.  Tracking the clonal origin of lethal prostate cancer.

Authors:  Michael C Haffner; Timothy Mosbruger; David M Esopi; Helen Fedor; Christopher M Heaphy; David A Walker; Nkosi Adejola; Meltem Gürel; Jessica Hicks; Alan K Meeker; Marc K Halushka; Jonathan W Simons; William B Isaacs; Angelo M De Marzo; William G Nelson; Srinivasan Yegnasubramanian
Journal:  J Clin Invest       Date:  2013-10-25       Impact factor: 14.808

10.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321
View more
  1 in total

1.  Primary Tumor Resection Decelerates Disease Progression in an Orthotopic Mouse Model of Metastatic Prostate Cancer.

Authors:  Johannes Linxweiler; Turkan Hajili; Philip Zeuschner; Michael D Menger; Michael Stöckle; Kerstin Junker; Matthias Saar
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.